Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study...

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• The D-CARE study evaluated denosumab for early-stage breast cancer patients at high risk of recurrence.
• The primary endpoint, bone metastasis-free survival (BMFS), was not met, necessitating analysis of secondary endpoints.

Purpose of the Study:

• To assess the efficacy of adjuvant denosumab compared to placebo in preventing bone metastases in early breast cancer.
• To explore the impact of denosumab on bone health outcomes in specific patient subgroups.

Main Methods:

• Phase 3, randomized, double-blind, placebo-controlled trial involving 4509 women with stage II/III breast cancer.
• Patients received denosumab or placebo for approximately 6 months, followed by placebo for up to 5 years.
• Exploratory analyses focused on bone-related endpoints and subgroup analyses by age and menopausal status.

Main Results:

• Denosumab did not significantly improve bone metastasis-free survival (HR 0.82, p=0.068).
• Significant benefits were observed in younger (<50 years) and premenopausal patients for time to first bone metastasis (HR 0.70 and 0.74, respectively).
• Denosumab significantly reduced the risk of on-study fractures (HR 0.76) and skeletal-related events (HR 0.52).

Conclusions:

• While the primary endpoint was not met, exploratory results suggest denosumab offers bone health benefits in high-risk early breast cancer.
• The drug's positive impact on fractures and skeletal-related events supports its role in managing bone complications.
• Subgroup analyses highlight potential efficacy in younger, premenopausal women, indicating a need for personalized treatment approaches.